Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.

[Guest guest]

Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in

chronic lymphocytic leukaemia with 17p deletion.

Francesco Forconi, Rinaldi, Ivo Kwee, Sozzi, Donatella Raspadori,

Paola M V Rancoita, Marta Scandurra, e Rossi, Clara Deambrogi, a

Capello, Emanuele Zucca, a Marconi, Riccardo Bomben, Valter Gattei,

Francesco Lauria, Gianluca Gaidano, and Francesco Bertoni

Br J Haematol, August 24, 2008; .

Sezione Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze

Immunologiche, Università di Siena, Siena, Italy.

Deletion of 17p (TP53) identifies a rare subset of chronic lymphocytic leukaemia

(17p- CLL) with aggressive behaviour. Genome-wide DNA-profiling was performed to

investigate 18 patients with 17p- CLL. All cases had multiple copy-number (CN)

changes. Among the several recurrent CN changes identified, 8q24.13-q24.1-gain

(MYC), 8p-loss (TNFRSF10A/B, also known as TRAIL1/2) and 2p16.1-p14-gain

(REL/BCL11A) appeared frequently represented. 8p-loss and 2p16.1-p14-gain also

appeared clinically relevant and predicted significant shorter time from

diagnosis to treatment (8p-loss) and overall survival (8p-loss and

2p16.1-p14-gain, P < 0.05). These observations document a highly unstable genome

in 17p- CLL and suggest that additional genes outside the TP53 locus may be

important for tumour behaviour.

PMID: 18752589